TrialSignal transduction and targeted therapy2024

Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.

Yan Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.